Biallelic TET2 mutations and canonical ASXL1 mutations are frequent and cooccur in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): An institutional experience and review of literature
暂无分享,去创建一个
G. Crane | E. Hsi | Yu-Wei Cheng | Xi Zhang
[1] Hannah C. Beird,et al. Divergent clonal evolution of blastic plasmacytoid dendritic cell neoplasm and chronic myelomonocytic leukemia from a shared TET2-mutated origin , 2021, Leukemia.
[2] Nikhil Gadewal,et al. miRNA–mRNA Profiling Reveals Prognostic Impact of SMC1A Expression in Acute Myeloid Leukemia , 2020, Oncology research.
[3] T. Haferlach,et al. Invariant phenotype and molecular association of biallelic TET2 mutant myeloid neoplasia. , 2019, Blood advances.
[4] S. Pileri,et al. Blastic plasmacytoid dendritic cell neoplasm: genomics mark epigenetic dysregulation as a primary therapeutic target , 2018, Haematologica.
[5] E. Solary,et al. Biallelic inactivation of the retinoblastoma gene results in transformation of chronic myelomonocytic leukemia to a blastic plasmacytoid dendritic cell neoplasm: shared clonal origins of two aggressive neoplasms , 2018, Blood Cancer Journal.
[6] A. Tefferi,et al. Chronic myelomonocytic leukemia: 2018 update on diagnosis, risk stratification and management , 2018, American journal of hematology.
[7] A. Lucia,et al. Mutations in the DNA methylation pathway and number of driver mutations predict response to azacitidine in myelodysplastic syndromes , 2017, Oncotarget.
[8] J. Delabie,et al. Cytogenetic studies on populations of Camponotus rufipes (Fabricius, 1775) and Camponotus renggeri Emery, 1894 (Formicidae: Formicinae) , 2017, PloS one.
[9] B. Falini,et al. Blastic plasmacytoid dendritic cell neoplasm and chronic myelomonocytic leukemia: a shared clonal origin , 2017, Leukemia.
[10] D. Neuberg,et al. TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. , 2014, Blood.
[11] L. Jeffrey Medeiros,et al. TET2 mutations, myelodysplastic features, and a distinct immunoprofile characterize blastic plasmacytoid dendritic cell neoplasm in the bone marrow , 2013, American journal of hematology.
[12] R. Majeti,et al. Role of DNMT3A, TET2, and IDH1/2 mutations in pre-leukemic stem cells in acute myeloid leukemia , 2013, International Journal of Hematology.
[13] Bob Löwenberg,et al. Acquired mutations in ASXL1 in acute myeloid leukemia: prevalence and prognostic value , 2012, Haematologica.
[14] D. Neuberg,et al. Clinical effect of point mutations in myelodysplastic syndromes. , 2011, The New England journal of medicine.
[15] F. Jardin,et al. TET2 and TP53 mutations are frequently observed in blastic plasmacytoid dendritic cell neoplasm , 2011, British journal of haematology.